Literature DB >> 6607839

Inhibition of T cell proliferation by antibodies to synthetic peptides.

J R Lamb, E D Zanders, P Lake, R G Webster, D D Eckels, J N Woody, N Green, R A Lerner, M Feldmann.   

Abstract

While T cell proliferation to antigen in the presence of antigen-presenting cells is well known to be readily inhibited by antibodies directed against Class II major histocompatibility complex (MHC) (Ia/HLA-DR) products, it has not been possible to inhibit proliferation by antibodies directed against the antigen. Because of the implications of these observations for targets of T cell recognition, this phenomenon was reinvestigated using human T cell clones, recognizing a small (24 amino acid) synthetic peptide (termed p20) derived from the influenza hemagglutinin-1 molecule. It was found that proliferation of clones to p20 was inhibited efficiently (less than 90%), using p20 as antigen, and rabbit anti-p20. Inhibition was possible either by coculturing p20 antigen and antibody to p20 with cloned T cells and antigen-presenting (E-) cells, or by pulsing antigen-presenting cells with antigen prior to a brief incubation with antibody before washing the E- cells and using them to stimulate cloned T cells. These results do not indicate why previous attempts had failed, but in view of the different techniques available now (cloned T cells, small synthetic polypeptides, and antibody raised against polypeptide) we investigated the influence of these parameters. It was found that, using cloned T cells, the form of the antigen was of importance, as antibody inhibition of the response to hemagglutinin or whole influenza A was much less apparent. These differences were interpreted as being due to greater access of anti-p20 to p20 than to hemagglutinin or influenza. If uncloned T cell lines were used, inhibition was also much harder to detect. This was interpreted as masking of inhibition of the response of some clones in the line by interleukin 2-induced recruitment.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6607839     DOI: 10.1002/eji.1830140209

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Inhibitory effects of monoclonal antibodies to a synthetic peptide of influenza haemagglutinin on the processing and presentation of viral antigens to class II-restricted T-cell clones.

Authors:  K H Mills
Journal:  Immunology       Date:  1988-11       Impact factor: 7.397

2.  Isolation of a T-cell clone that reacts with both antigen and anti-idiotype: evidence for anti-idiotype as internal image for antigen at the T-cell level.

Authors:  R Singhai; J G Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

Review 3.  Leishmaniasis: current status of vaccine development.

Authors:  E Handman
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

4.  The role of serum factors in the suppression of experimental allergic encephalomyelitis: evidence for immunoregulation by antibody to the encephalitogenic peptide.

Authors:  I A MacPhee; M J Day; D W Mason
Journal:  Immunology       Date:  1990-08       Impact factor: 7.397

5.  Human T-helper lymphocytes in myasthenia gravis recognize the nicotinic receptor alpha subunit.

Authors:  R Hohlfeld; K V Toyka; S J Tzartos; W Carson; B M Conti-Tronconi
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

6.  Major histocompatibility complex non-restricted presentation to CD4+ T lymphocytes of Mycobacterium leprae heat-shock protein 65 antigen by macrophages transfected with the mycobacterial gene.

Authors:  C L Silva; K Lukacs; D B Lowrie
Journal:  Immunology       Date:  1993-01       Impact factor: 7.397

7.  Vaccine Development Against Leishmania donovani.

Authors:  Amrita Das; Nahid Ali
Journal:  Front Immunol       Date:  2012-05-15       Impact factor: 7.561

8.  Immunologically relevant peptide antigen exists on the presenting cell in a manner accessible to macromolecules in solution.

Authors:  K B Cease; G Buckenmeyer; I Berkower; J York-Jolley; J A Berzofsky
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.